Cat. No. 0905

Rolipram C16H21NO3 [61413-54-5]

Price and Availability

For Rolipram pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 4-(3-(Cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one

Biological Activity

Selective inhibitor of cAMP phosphodiesterase (PDE4) (IC50 = 2.0 μM). Discriminates between two conformational states of PDE4 isoenzymes. Separate isomers (R)-(-)-Rolipram and (S)-(+)-Rolipram are available (Cat. Nos. 1349 and 1350 respectively).

Technical Data

Soluble to 75 mM in DMSO and to 75 mM in ethanol
>98 %
Store at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet


O'Donnell (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behaviour maintained by differential reinforcement of low response rate. J.Pharmacol.Exp.Ther. 264 1168. PMID: 8383740.

Kato et al (1995) Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil. Eur.J.Pharmacol. 272 107. PMID: 7713141.

Teixeira et al (1997) Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol.Sci. 18 164. PMID: 9184477.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

View Related Products by Product Action

Keywords: Rolipram, supplier, PDE4, inhibitor, Phosphodiesterases, Phosphodiesterase Inhibitors

Quick Order

Find multiple products by catalog number

divider line

Cardiovascular Research Product Guide

Cardiovascular Research Product Guide

Highlights over 250 products for cardiovascular research. Request copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Life Science Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development. Request copy today.

divider line

New Products in this Area

UPF 648

Potent kynurenine 3-monooxygenase (KMO) inhibitor

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Pharmacology 2015

Pharmacology 2015

December 15 - 17, 2015

London UK